The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population

Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Younossi, 2016, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe, Hepatology, 64, 1577, 10.1002/hep.28785 Setiawan, 2016, Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort, Hepatology, 64, 1969, 10.1002/hep.28677 Noureddin, 2018, NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances, Am J Gastroenterol, 113, 1649, 10.1038/s41395-018-0088-6 Dokmak, 2020, The impact of non-alcoholic fatty liver disease in primary care: a population health perspective, Am J Med Association AD, 2020, Improving care and promoting health in populations: standards of medical care in Diabetes-2020, Diabetes Care, 43, S7, 10.2337/dc20-S001 Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367 2016, EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, 64, 1388, 10.1016/j.jhep.2015.11.004 Angulo, 1999, Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis, Hepatology, 30, 1356, 10.1002/hep.510300604 Yang, 2019, Diabetes is associated with increased risk of hepatocellular carcinoma in cirrhosis patients with nonalcoholic fatty liver disease, Hepatology Labenz, 2018, Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany, Aliment Pharmacol Ther, 48, 1109, 10.1111/apt.14976 Mofrad, 2003, Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values, Hepatology, 37, 1286, 10.1053/jhep.2003.50229 McPherson, 2015, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management, J Hepatol, 62, 1148, 10.1016/j.jhep.2014.11.034 Stepanova, 2013, Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD), Dig Dis Sci, 58, 3017, 10.1007/s10620-013-2743-5 Kwok, 2016, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265 Doycheva, 2016, Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE, Aliment Pharmacol Ther, 43, 83, 10.1111/apt.13405 Tapper, 2017, 2296 Tapper, 2015, Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography, Am J Gastroenterol, 110, 1298, 10.1038/ajg.2015.241 Bureau, 2008, Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease, Aliment Pharmacol Ther, 27, 1261, 10.1111/j.1365-2036.2008.03701.x Lemoine, 2008, Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis, Aliment Pharmacol Ther, 28, 1102, 10.1111/j.1365-2036.2008.03825.x Trivedi, 2017, Noninvasive assessment of fibrosis regression in hepatitis C virus sustained virologic responders, Gastroenterol Hepatol (N Y), 13, 587 Budd, 2020, Nonalcoholic fatty liver disease: what does the primary care physician need to know?, Am J Med, 10.1016/j.amjmed.2020.01.007 Williams, 2014, Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis, Lancet, 384, 1953, 10.1016/S0140-6736(14)61838-9 McLernon, 2009, Health outcomes following liver function testing in primary care: a retrospective cohort study, Fam Pract, 26, 251, 10.1093/fampra/cmp025 Fracanzani, 2008, Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes, Hepatology, 48, 792, 10.1002/hep.22429 Wong, 2009, Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels, Aliment Pharmacol Ther, 29, 387, 10.1111/j.1365-2036.2008.03896.x Chalmers, 2020, The development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community, Frontline Gastroenterol, 11, 86, 10.1136/flgastro-2019-101177 Davyduke, 2019, Impact of implementing a “FIB-4 first” strategy on a pathway for patients with NAFLD referred from primary care, Hepatol Commun., 3, 1322, 10.1002/hep4.1411 Srivastava, 2019, Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease, BMC Gastroenterol, 19, 122, 10.1186/s12876-019-1039-4 Younossi, 2019, Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 394, 2184, 10.1016/S0140-6736(19)33041-7 Dokmak, 2019, Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease, World J Hepatol, 11, 562, 10.4254/wjh.v11.i7.562